APAC Nasal Spray Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Asia-Pacific nasal spray market is projected to register a CAGR of 7.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Asia-Pacific Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care), Country (China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific nasal spray market are:

Rise in the therapeutic application of the nasal spray

Increase in the demand for nasal sprays for allergic diseases and pandemics such as COVID-19

Market Players

Some of the major market players operating in the Asia-Pacific nasal spray market are:

EMERGENT

Cipla Inc.

Sandoz International GmbH (A Part of Novartis)

Aytu Health (A subsidiary of Aytu BioPharma, Inc.)

Bayer AG

GlaxoSmithKline plc.

Assertio Therapeutics, Inc.

Aurena Laboratories.

J Pharmaceuticals

St. Renatus.

Ultratech India Limited

Catalent, Inc.

Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd)

Pfizer Inc.

Viatris Inc.

LEEFORD HEALTHCARE LTD

Aishwarya Group

1 INTRODUCTION 23

1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25

2 MARKET SEGMENTATION 27

2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38

3 EXECUTIVE SUMMARY 39

4 PREMIUM INSIGHTS 42

4.1 PORTER'S FIVE FORCES MODEL 43
4.2 PESTEL ANALYSIS 44

5 INDUSTRY INSIGHTS: ASIA PACIFIC NASAL SPRAY MARKET 45

5.1 INDUSTRY INSIGHTS 45

6 REGULATIONS: ASIA PACIFIC NASAL SPRAY MARKET 46

6.1 REGULATORY SCENARIO IN INDIA 48
6.2 REGULATORY SCENARIO IN CHINA 48

7 MARKET OVERVIEW 49

7.1 DRIVERS 51
- 7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 51
- 7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 51
- 7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 52
- 7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 53
7.2 RESTRAINTS 54
- 7.2.1 PRODUCT RECALLS 54
- 7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 55
7.3 OPPORTUNITIES 56
- 7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 56
- 7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 56
- 7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 57
7.4 CHALLENGES 57
- 7.4.1 REGULATORY HURDLES 57
- 7.4.2 ADDICTION TO NASAL SPRAY 58

8 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE 59

8.1 OVERVIEW 60
8.2 DECONGESTION NASAL SPRAY 63
8.3 STEROID NASAL SPRAY 64
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 65
8.5 OTHERS 66

9 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN 67

9.1 OVERVIEW 68
9.2 PUMP BOTTLES 71
9.3 PRESSURIZED CANISTERS 72

10 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM 73

10.1 OVERVIEW 74
10.2 MULTI DOSE 77
10.3 UNIT/SINGLE DOSE 78
10.4 BI DOSE 79

11 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 81

11.1 OVERVIEW 82
11.2 ANTIHISTAMINE 85
11.3 NASAL STEROIDS 86
11.4 MAST CELL INHIBITOR 87
11.5 ANTICHOLINERGIC 88

12 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION 89

12.1 OVERVIEW 90
12.2 NASAL CONGESTION 93
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 94
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 95
12.5 VACCINATION 96
12.6 OTHERS 97

13 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 98

13.1 OVERVIEW 99
13.2 PRESCRIBED 102
13.3 OVER THE COUNTER 103

14 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER 105

14.1 OVERVIEW 106
14.2 HOME CARE SETTINGS 109
14.3 HOSPITALS 110
14.4 CLINICS 111
14.5 COMMUNITY HEALTH CARE 112

15 ASIA PACIFIC NASAL SPRAY MARKET, BY REGION 113

15.1 ASIA-PACIFIC 114
- 15.1.1 CHINA 122
- 15.1.2 JAPAN 124
- 15.1.3 INDIA 126
- 15.1.4 AUSTRALIA 128
- 15.1.5 SOUTH KOREA 130
- 15.1.6 MALAYSIA 132
- 15.1.7 THAILAND 134
- 15.1.8 SINGAPORE 136
- 15.1.9 INDONESIA 138
- 15.1.10 PHILIPPINES 140
- 15.1.11 REST OF ASIA-PACIFIC 142

16 ASIA PACIFIC NASAL SPRAY MARKET, COMPANY LANDSCAPE 143

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 143

17 SWOT ANALYSIS 144

18 COMPANY PROFILE 145

18.1 GLAXOSMITHKLINE PLC. 145
- 18.1.1 COMPANY SNAPSHOT 145
- 18.1.2 REVENUE ANALYSIS 145
- 18.1.3 COMPANY SHARE ANALYSIS 146
- 18.1.4 PRODUCT PORTFOLIO 146
- 18.1.5 RECENT DEVELOPMENTS 146
18.2 PFIZER INC. 148
- 18.2.1 COMPANY SNAPSHOT 148
- 18.2.2 REVENUE ANALYSIS 148
- 18.2.3 COMPANY SHARE ANALYSIS 149
- 18.2.4 PRODUCT PORTFOLIO 149
- 18.2.5 RECENT DEVELOPMENTS 149
18.3 EMERGENT 151
- 18.3.1 COMPANY SNAPSHOT 151
- 18.3.2 REVENUE ANALYSIS 151
- 18.3.3 COMPANY SHARE ANALYSIS 152
- 18.3.4 PRODUCT PORTFOLIO 152
- 18.3.5 RECENT DEVELOPMENT 152
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 153
- 18.4.1 COMPANY SNAPSHOT 153
- 18.4.2 REVENUE ANALYSIS 153
- 18.4.3 COMPANY SHARE ANALYSIS 154
- 18.4.4 PRODUCT PORTFOLIO 154
- 18.4.5 RECENT DEVELOPMENT 154
18.5 CATALENT, INC. 155
- 18.5.1 COMPANY SNAPSHOT 155
- 18.5.2 REVENUE ANALYSIS 155
- 18.5.3 COMPANY SHARE ANALYSIS 156
- 18.5.4 PRODUCT PORTFOLIO 156
- 18.5.5 RECENT DEVELOPMENTS 156
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 158
- 18.6.1 COMPANY SNAPSHOT 158
- 18.6.2 REVENUE ANALYSIS 158
- 18.6.3 PRODUCT PORTFOLIO 159
- 18.6.4 RECENT DEVELOPMENTS 159
18.7 AISHWARYA GROUP 160
- 18.7.1 COMPANY SNAPSHOT 160
- 18.7.2 PRODUCT PORTFOLIO 160
- 18.7.3 RECENT DEVELOPMENTS 160
18.8 ASSERTIO THERAPEUTICS, INC. 161
- 18.8.1 COMPANY SNAPSHOT 161
- 18.8.2 REVENUE ANALYSIS 161
- 18.8.3 PRODUCT PORTFOLIO 162
- 18.8.4 RECENT DEVELOPMENT 162
18.9 AURENA LABORATORIES. 163
- 18.9.1 COMPANY SNAPSHOT 163
- 18.9.2 PRODUCT PORTFOLIO 163
- 18.9.3 RECENT DEVELOPMENTS 163
18.10 BAYER AG 165
- 18.10.1 COMPANY SNAPSHOT 165
- 18.10.2 REVENUE ANALYSIS 165
- 18.10.3 COMPANY SHARE ANALYSIS 166
- 18.10.4 PRODUCT PORTFOLIO 166
- 18.10.5 RECENT DEVELOPMENTS 166
18.11 CIPLA INC. 168
- 18.11.1 COMPANY SNAPSHOT 168
- 18.11.2 REVENUE ANALYSIS 168
- 18.11.3 PRODUCT PORTFOLIO 169
- 18.11.4 RECENT DEVELOPMENT 169
18.12 J PHARMACEUTICALS. 170
- 18.12.1 COMPANY SNAPSHOT 170
- 18.12.2 PRODUCT PORTFOLIO 170
- 18.12.3 RECENT DEVELOPMENTS 170
18.13 LEEFORD HEALTHCARE LTD 171
- 18.13.1 COMPANY SNAPSHOT 171
- 18.13.2 PRODUCT PORTFOLIO 171
- 18.13.3 RECENT DEVELOPMENTS 171
18.14 ST. RENATUS. 172
- 18.14.1 COMPANY SNAPSHOT 172
- 18.14.2 PRODUCT PORTFOLIO 172
- 18.14.3 RECENT DEVELOPMENTS 172
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 173
- 18.15.1 COMPANY SNAPSHOT 173
- 18.15.2 REVENUE ANALYSIS 173
- 18.15.3 PRODUCT PORTFOLIO 174
- 18.15.4 RECENT DEVELOPMENTS 174
18.16 ULTRATECH INDIA LIMITED 175
- 18.16.1 COMPANY SNAPSHOT 175
- 18.16.2 PRODUCT PORTFOLIO 175
- 18.16.3 RECENT DEVELOPMENTS 175
18.17 VIATRIS INC. 176
- 18.17.1 COMPANY SNAPSHOT 176
- 18.17.2 REVENUE ANALYSIS 176
- 18.17.3 COMPANY SHARE ANALYSIS 177
- 18.17.4 PRODUCT PORTFOLIO 177
- 18.17.5 RECENT DEVELOPMENT 177

19 QUESTIONNAIRE 178

20 RELATED REPORTS 182

LIST OF TABLES

TABLE 1 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 56
TABLE 2 ASIA PACIFIC DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 3 ASIA PACIFIC STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 4 ASIA PACIFIC SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 5 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 6 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 64
TABLE 7 ASIA PACIFIC PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 8 ASIA PACIFIC PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 9 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 70
TABLE 10 ASIA PACIFIC MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 11 ASIA PACIFIC UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 12 ASIA PACIFIC BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 13 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 78
TABLE 14 ASIA PACIFIC ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 15 ASIA PACIFIC NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 16 ASIA PACIFIC MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 17 ASIA PACIFIC ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 18 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 86
TABLE 19 ASIA PACIFIC NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 20 ASIA PACIFIC ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 21 ASIA PACIFIC CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 22 ASIA PACIFIC VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 23 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 24 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 95
TABLE 25 ASIA PACIFIC PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 26 ASIA PACIFIC OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 27 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 102
TABLE 28 ASIA PACIFIC HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 29 ASIA PACIFIC HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 30 ASIA PACIFIC CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 31 ASIA PACIFIC COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 32 ASIA-PACIFIC NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 113
TABLE 33 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
TABLE 34 ASIA-PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 113
TABLE 35 ASIA-PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 114
TABLE 36 ASIA-PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 114
TABLE 37 ASIA-PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 114
TABLE 38 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 114
TABLE 39 ASIA-PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 40 CHINA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116
TABLE 41 CHINA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 116
TABLE 42 CHINA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 116
TABLE 43 CHINA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 116
TABLE 44 CHINA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 117
TABLE 45 CHINA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 117
TABLE 46 CHINA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 117
TABLE 47 JAPAN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 48 JAPAN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 118
TABLE 49 JAPAN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 118
TABLE 50 JAPAN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 118
TABLE 51 JAPAN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 119
TABLE 52 JAPAN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 119
TABLE 53 JAPAN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 119
TABLE 54 INDIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120
TABLE 55 INDIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 120
TABLE 56 INDIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 120
TABLE 57 INDIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 120
TABLE 58 INDIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 121
TABLE 59 INDIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 121
TABLE 60 INDIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 121
TABLE 61 AUSTRALIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 62 AUSTRALIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 122
TABLE 63 AUSTRALIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 122
TABLE 64 AUSTRALIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 122
TABLE 65 AUSTRALIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 123
TABLE 66 AUSTRALIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 123
TABLE 67 AUSTRALIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 123
TABLE 68 SOUTH KOREA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 69 SOUTH KOREA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 124
TABLE 70 SOUTH KOREA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 124
TABLE 71 SOUTH KOREA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 124
TABLE 72 SOUTH KOREA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 125
TABLE 73 SOUTH KOREA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 125
TABLE 74 SOUTH KOREA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 125
TABLE 75 MALAYSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 76 MALAYSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 126
TABLE 77 MALAYSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 126
TABLE 78 MALAYSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 126
TABLE 79 MALAYSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 127
TABLE 80 MALAYSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 127
TABLE 81 MALAYSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 127
TABLE 82 THAILAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 83 THAILAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 128
TABLE 84 THAILAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 128
TABLE 85 THAILAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 128
TABLE 86 THAILAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
TABLE 87 THAILAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 129
TABLE 88 THAILAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 129
TABLE 89 SINGAPORE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 130
TABLE 90 SINGAPORE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 130
TABLE 91 SINGAPORE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 130
TABLE 92 SINGAPORE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 130
TABLE 93 SINGAPORE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 94 SINGAPORE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 131
TABLE 95 SINGAPORE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 131
TABLE 96 INDONESIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 97 INDONESIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 132
TABLE 98 INDONESIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 132
TABLE 99 INDONESIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 132
TABLE 100 INDONESIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 133
TABLE 101 INDONESIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 133
TABLE 102 INDONESIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 133
TABLE 103 PHILIPPINES NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 104 PHILIPPINES NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 134
TABLE 105 PHILIPPINES NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 134
TABLE 106 PHILIPPINES NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 134
TABLE 107 PHILIPPINES NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 135
TABLE 108 PHILIPPINES NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 135
TABLE 109 PHILIPPINES NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 110 REST OF ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION 20
FIGURE 2 ASIA PACIFIC NASAL SPRAY MARKET: DATA TRIANGULATION 23
FIGURE 3 ASIA PACIFIC NASAL SPRAY MARKET: DROC ANALYSIS 24
FIGURE 4 ASIA PACIFIC NASAL SPRAY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 25
FIGURE 5 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 6 ASIA PACIFIC NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS 27
FIGURE 7 ASIA PACIFIC NASAL SPRAY MARKET: DBMR MARKET POSITION GRID 28
FIGURE 8 ASIA PACIFIC NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID 29
FIGURE 9 ASIA PACIFIC NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 10 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION 34
FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE ASIA PACIFIC NASAL SPRAY MARKET IN THE FORECAST PERIOD 35
FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC NASAL SPRAY MARKET IN 2023 AND 2030 35
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC NASAL SPRAY MARKET 43
FIGURE 14 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022 53
FIGURE 15 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 54
FIGURE 16 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 54
FIGURE 17 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 55
FIGURE 18 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022 61
FIGURE 19 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION) 62
FIGURE 20 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030) 62
FIGURE 21 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE 63
FIGURE 22 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2022 67
FIGURE 23 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION) 68
FIGURE 24 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030) 68
FIGURE 25 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE 69
FIGURE 26 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022 75
FIGURE 27 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION) 76
FIGURE 28 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030) 76
FIGURE 29 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE 77
FIGURE 30 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2022 83
FIGURE 31 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 84
FIGURE 32 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030) 84
FIGURE 33 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE 85
FIGURE 34 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022 92
FIGURE 35 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION) 93
FIGURE 36 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030) 93
FIGURE 37 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE 94
FIGURE 38 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2022 99
FIGURE 39 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION) 100
FIGURE 40 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030) 100
FIGURE 41 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE 101
FIGURE 42 ASIA-PACIFIC NASAL SPRAY MARKET: SNAPSHOT (2022) 108
FIGURE 43 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022) 110
FIGURE 44 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030) 110
FIGURE 45 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030) 111
FIGURE 46 ASIA-PACIFIC NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030) 111
FIGURE 47 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY SHARE 2022 (%) 136